Mimedx (MDXG) Return on Capital Employed (2011 - 2026)
Mimedx recorded quarterly Return on Capital Employed of 14.08% in Q1 2026, down 41.24% quarter-over-quarter from 23.97% in Q4 2025, and down 993.0% year-over-year from 1.58% in Q1 2025.
Mimedx's Return on Capital Employed history runs 15 years deep, the most recent figure standing at 14.08% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 993.0% year-over-year to 14.08%; the TTM figure through Mar 2026 stood at 14.08% (down 993.0% YoY), while the FY2025 annual figure was 26.73%, down 186.0% from the prior year.
- Return on Capital Employed came in at 14.08% for Q1 2026 at Mimedx, down from 23.97% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 34.03% in Q2 2024 to a low of 19.82% in Q3 2022.
- A 5-year average of 13.24% and a median of 21.78% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 4350 bps in 2023 and tumbled 1544 bps in 2025, its largest moves.
- Mimedx's Return on Capital Employed stood at 11.46% in 2022, then jumped by 293 bps to 22.09% in 2023, then climbed by 28 bps to 28.26% in 2024, then fell by 15 bps to 23.97% in 2025, then tumbled by 41 bps to 14.08% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 14.08%, 23.97%, and 21.78% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | 14.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.08% |
| Dec 31, 2025 | 23.97% |
| Sep 30, 2025 | 21.78% |
| Jun 30, 2025 | 18.59% |
| Mar 31, 2025 | 24.01% |
| Dec 31, 2024 | 28.26% |
| Sep 30, 2024 | 32.45% |
| Jun 30, 2024 | 34.03% |
| Mar 31, 2024 | 26.92% |
| Dec 31, 2023 | 22.09% |
| Sep 30, 2023 | 23.68% |
| Jun 30, 2023 | 11.51% |
| Mar 31, 2023 | -4.47% |
| Dec 31, 2022 | -11.46% |
| Sep 30, 2022 | -19.82% |
| Jun 30, 2022 | -13.93% |
| Mar 31, 2022 | -6.57% |
| Dec 31, 2021 | -4.97% |
| Sep 30, 2021 | -17.19% |
| Jun 30, 2021 | -23.89% |
| Mar 31, 2021 | -27.31% |
| Dec 31, 2020 | -30.57% |
| Sep 30, 2020 | -27.38% |
| Jun 30, 2020 | -11.26% |
| Mar 31, 2020 | -21.63% |
| Dec 31, 2019 | -19.98% |
| Sep 30, 2019 | -24.88% |
| Jun 30, 2019 | -64.26% |
| Mar 31, 2019 | -39.94% |
| Dec 31, 2017 | 44.37% |
| Sep 30, 2017 | 8.69% |
| Jun 30, 2017 | 6.49% |
| Mar 31, 2017 | 5.42% |
| Dec 31, 2016 | 1.00% |
| Sep 30, 2016 | 12.69% |
| Jun 30, 2016 | 14.06% |
| Mar 31, 2016 | 16.90% |
| Dec 31, 2015 | 23.39% |
| Sep 30, 2015 | 22.26% |
| Jun 30, 2015 | 20.20% |
| Mar 31, 2015 | 13.72% |
| Dec 31, 2014 | 8.36% |
| Sep 30, 2014 | 1.34% |
| Jun 30, 2014 | -3.84% |
| Mar 31, 2014 | -4.32% |
| Dec 31, 2013 | -4.76% |
| Sep 30, 2013 | -6.38% |
| Jun 30, 2013 | -16.94% |
| Mar 31, 2013 | -16.21% |
| Dec 31, 2012 | -18.25% |
| Sep 30, 2012 | -34.17% |
| Jun 30, 2012 | -25.56% |
| Mar 31, 2012 | -35.36% |
| Dec 31, 2011 | -47.40% |